DYN
Dyne Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +1 | 73.73M | $1.63B | +7 | −5 |
| Q1 2026 | 87 | -4 | 78.51M | $1.42B | +7 | −12 |
| Q4 2025 | 92 | 0 | 87.58M | $1.71B | +2 | −1 |
| Q3 2025 | 18 | +1 | 57.06M | $721.88M | +1 | −1 |
| Q2 2025 | 15 | +2 | 34.50M | $328.45M | +2 | — |
| Q1 2025 | 10 | -1 | 12.46M | $130.33M | +1 | −2 |
| Q4 2024 | 11 | 0 | 14.93M | $351.71M | +1 | −1 |
| Q3 2024 | 10 | -2 | 10.58M | $380.14M | +1 | −3 |
| Q2 2024 | 12 | — | 13.13M | $463.42M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 4.32M | — | $152.31M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 3.33M | — | $117.45M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.37M | — | $83.50M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 1.77M | — | $62.64M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 357.52K | — | $12.62M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 273.57K | — | $9.65M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 226.42K | — | $7.99M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | Two Sigma Investments ✦ | 159.15K | — | $5.62M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 126.00K | — | $4.45M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Norges Bank ✦ (passive) | 107.09K | — | $3.78M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 88.42K | — | $3.12M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 8.49K | — | $299,788 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 226 holders, 184.59M shares, $2.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 2.50K sh @ 16.00 · $40,000
Open-market sales (S)
Officer, Director · 5.66K sh · $106,823
Officer · 1.29K sh · $24,355
Officer · 185 sh · $3,493
Officer · 3.75K sh · $91,191
Officer · 900 sh · $21,915
Director · 478.38K sh · $11.96M
Director · 1.36M sh · $33.99M
Director · 322.46K sh · $8.06M
Officer · 1.56K sh · $40,892
Director · 268.35K sh · $7.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology